Literature DB >> 25905569

Symptom management in inflammatory bowel disease.

Bincy P Abraham1.   

Abstract

Patients with inflammatory bowel disease can present with a wide variety of symptoms. Most are related to disease activity and should be managed with appropriate medical therapy for inflammatory bowel disease. However, some patients may develop symptoms due to the side effects of the medications, or due to immunosuppression. In these cases, the offending medications should be discontinued until resolution of the symptoms and a few may be able to restart therapy. Symptoms can also occur as an extraintestinal manifestation of the disease or due to concomitant autoimmune-mediated disorders. Regardless of the etiology, symptoms should be addressed promptly with immediate evaluation and appropriate therapy, as a delay may lead to permanent sequela.

Entities:  

Keywords:  abdominal pain; alopecia; anxiety and depression; diarrhea; dyspnea; fatigue; inflammatory bowel disease; joint pain; nausea and vomiting; neurologic symptoms

Mesh:

Substances:

Year:  2015        PMID: 25905569     DOI: 10.1586/17474124.2015.1038241

Source DB:  PubMed          Journal:  Expert Rev Gastroenterol Hepatol        ISSN: 1747-4124            Impact factor:   3.869


  3 in total

1.  Irritable Inflammatory Bowel Syndrome as a Distinct Disease Entity.

Authors:  Jung Hwan Oh
Journal:  J Neurogastroenterol Motil       Date:  2016-10-30       Impact factor: 4.924

2.  Desmethylbellidifolin From Gentianella acuta Ameliorate TNBS-Induced Ulcerative Colitis Through Antispasmodic Effect and Anti-Inflammation.

Authors:  Yajuan Ni; Mengyang Liu; Haiyang Yu; Yue Chen; Yanxia Liu; Suyile Chen; Jingya Ruan; Alatengchulu Da; Yi Zhang; Tao Wang
Journal:  Front Pharmacol       Date:  2019-09-20       Impact factor: 5.810

Review 3.  Mesenchymal stem/stromal cells in the pathogenesis and regenerative therapy of inflammatory bowel diseases.

Authors:  Zhengping Che; Ziyu Ye; Xueying Zhang; Bihua Lin; Weiqing Yang; Yanfang Liang; Jincheng Zeng
Journal:  Front Immunol       Date:  2022-08-04       Impact factor: 8.786

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.